EFFICACY OF 5MG AND 10MG ROSUVASTATIN IN TYPE 2 DIABETES MELLITUS WITH YPERCHOLESTEROALEMIA
AbstractBackground: Coronary Heart Disease (CHD) is the most important complication and the leading cause of death in patients with type 2 diabetes mellitus (T2DM). Hypercholesterolemia is an important modifiable risk factor for CHD. Statins are the first line drugs for the treatment of hypercholesterolemia in DM. Comparative studies between different statins are available but different doses of the same statin have not been compared in our population. The objective of this study is to compare mean reduction in serum LDL-C level after using 5mg and 10mg of rosuvastatin among T2DM patients with hypercholesterolemia. This study will help finding lowest effective dose of rosuvastatin to achieve internationally set low density lipoprotein cholesterol (LDL-C) goals. Methods: A total of 82 patients with T2DM having fasting LDL-C levels equal or more than 100mg/dl were randomly allocated into two groups with 41 patients in each group. Baseline fasting serum LCL-C levels were obtained in all patients. Group A received 5mg while group B received 10mg of rosuvastatin daily at night. After 6 weeks, fasting LDL-C levels were obtained and analysed to compare the mean±SD reduction of LDL-C levels in both groups. Results: Baseline mean± SD LDL-C levels in group A and group B were 134.12±30.02 and 143.49±32.01 respectively (p 0.176). Follow up mean±SD LDL-C levels were 81.59±28.47 and 83.24±36.06respectively (p 0.818). Mean± SD reduction in LDL-C levels from baseline levels in group A and group B were 52.51±19.49 and 60.20±24.09 (p 0.116). Conclusion: Rosuvastatin 5mg is as effective as 10mg in reducing the LDL-C levels in type 2 diabetic patients with hypercholesterolemia.
The International Diabetes Federation. Diabetes epidemic out of control [online]. [Cited on December 4, 2006].
Powers AC. Diabetes mellitus. In: Fauci AS, Kasper DL, Longo DL, Braunwald E, Hauser SL, Jameson JL, et al, editors. Harrison's Principles of Internal Medicine. New York: The McGraw-Hill; 2008.p.2276–92.
Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010;87(1):4–14.
Frier BM, Fisher M. Diabetes Mellitus. In: Colledge NR, Walker BR, Ralston SH, editors. Davidson’s Principles and Practice of Medicine. New Delhi: Elsevier; 2010.p.798.
Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 2007;30(1):162–72.
Yusuf S, Lonn E, Bosch J. Lipid lowering for primary prevention. Lancet 2009;373(9670):1152–5.
Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomized trials of statins: A meta-analysis. Lancet 2008;371(9607):117–25.
Fox KM, Gandhi SK, Ohsfeldt RL, Blasetto JW, Bays HE. Effectiveness of rosuvastatin in low-density lipoprotein cholesterol lowering and National Cholesterol Education Program Adult Treatment Panel guideline III LDL goal attainment compared to other statins among diabetes mellitus patients: A retrospective study using an electronic medical records dataset in the United States. Curr Med Res Opin 2007;23(9):2125–33.
Khan S, Abrar A, Rafique A, Abid AR, Jan T. Efficacy and safety of rosuvastatin compared to simvastatin in coronary artery disease. Gomal J Med Sci 2010;8(1):64–9.
Bullano MF, Kamat S, Wertz DA, Borok GM, Gandhi SK, McDonough KL, et al. Effectiveness of Rosuvastatin versus Atorvastatin in Reducing Lipid Levels and Achieving Low-density-lipoprotein Cholesterol Goals in a Usual Care Setting. Am J Health-Syst Pharm 2007;64(3):276–84.
Ho RH, Choi L, Lee W, Mayo G, Schwarz UI, Tirona RG, et al. Effect of drug transporter genotypes on pravastatin disposition in European and African-American participants. Pharmacogenet& Genomics 2007;17(8):647–56.
McPherson R, Frohlich J, Fodor G, Genest J, Canadian Cardiovascular Society. Canadian Cardiovascular Society position statement--recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol 2006;22(11):913–27.
Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366(9493):1267–78.
Clearfield MB, Amerena J, Bassand JP, Hernández García HR, Miller SS, Sosef FF, et al. Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia—Prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR.) Trials 2006;7:35–45.
Brown WV, Bays HE, Hassman DR, McKenney J, Chitra R, Hutchinson H, et al. Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial. Am Heart J 2002;144(6):1036–43.
Glueck CJ, Aregawi D, Agloria M, Khalil Q, Winiarska M, Munjal J, et al. Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies. Clin ther 2006;28(6):933–42
Viigimaa M, Vaverkova H, Farnier M, Averna M, Missault L, Hanson ME, et al. Ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk hypercholesterolemic patients stratified by prior statin treatment potency. Lipids Health Dis 2010;9:127–34.
Wolffenbuttel BH, Franken AA, Vincent HH; Dutch corall Study Group. Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes -- CORALL study. J Intern Med 2005;257(6):531–9.
Berne C, Siewert-Delle A; URANUS study investigators. Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study. Cardiovasc Diabetol 2005;3:4–7.
Laks T, Keba E, Leiner M, Merilind E, Petersen M, Reinmets S, et al. Achieving lipid goals with rosuvastatin compared with simvastatin in high risk patients in real clinical practice: a randomized, open-label, parallel-group, multicenter study: the DISCOVERY-Beta study. Vasc Health Risk Manag 2008;4:407–16.
Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol 2003;92(2):152-60.
Adsule SM, Baig MS, Gade PR, Khandelwal PN. A comparative evaluation of safety and efficacy of rosuvastatin, simvastatin, and atorvastatin in patients of type 2 diabetes mellitus with dyslipidemia. Int J Diabetes Dev Ctries 2009;29(2):74–9.